Epigallocatechin‐3‐gallate attenuates arsenic‐induced fibrogenic changes in human kidney epithelial cells through reversal of epigenetic aberrations and antioxidant activities
- 26 December 2023
- journal article
- research article
- Published by Wiley in BioFactors
- Vol. 50 (3) , 542-557
Abstract
Renal fibrosis is a pathogenic intermediate stage of chronic kidney disease (CKD). Nephrotoxicants including arsenic can cause kidney fibrosis through induction of oxidative stress and epigenetic aberrations. Epigallocatechin‐3‐gallate (EGCG), a green tea polyphenol, is known to have antioxidant and epigenetic modulation properties. Whether EGCG, through its antioxidant and epigenetic modulating activities, can attenuate fibrogenesis is not known. Therefore, the objective of this study was to determine whether EGCG can attenuate arsenic‐induced acute injury and long‐term exposure associated fibrogenicity in kidney epithelial cells. To address this question, two human kidney epithelial cell lines Caki‐1 and HK‐2 exposed to arsenic for both acute and long‐term durations were treated with EGCG. The protective effect of EGCG on arsenic‐induced cytotoxicity and fibrogenicity were evaluated by measuring the cell growth, reactive oxygen species (ROS) production, genes expression, and epigenetic changes in histone marks. Results revealed that EGCG has a protective effect in arsenic‐induced acute cytotoxicity in these cells. EGCG scavenges the increased levels of ROS in arsenic exposed cells. Aberrant expression of fibrogenic genes in arsenic exposed cells were restored by EGCG. Abrogation of arsenic‐induced fibrogenic changes was also associated with EGCG‐mediated restoration of arsenic‐induced aberrant expression of epigenetic regulatory proteins and histone marks. Novel findings of this study suggest that EGCG, through its antioxidant and epigenetic modulation capacities, has protective effects against arsenic‐induced cytotoxicity and fibrogenic changes in kidney epithelial cells.Keywords
Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases (R15DK121362‐01A1)
This publication has 58 references indexed in Scilit:
- Progression of Kidney Disease in Non-Diabetic Patients with Coronary Artery Disease: Predictive Role of Circulating Matrix Metalloproteinase-2, -3, and -9PLOS ONE, 2013
- Epigallocatechin-3-gallate prevents systemic inflammation-induced memory deficiency and amyloidogenesis via its anti-neuroinflammatory propertiesThe Journal of Nutritional Biochemistry, 2013
- Selenium mediated arsenic toxicity modifies cytotoxicity, reactive oxygen species and phosphorylated proteinsMetallomics, 2013
- (-)-Epigallocatechin-3-gallate reactivates silenced tumor suppressor genes, Cip1/p21 and p16INK4a, by reducing DNA methylation and increasing histones acetylation in human skin cancer cellsCarcinogenesis, 2011
- Effects Of Arsenic Exposure On Dna Methylation And Epigenetic Gene RegulationEpigenomics, 2010
- Histone deacetylase modulates the proinflammatory and -fibrotic changes in tubulointerstitial injuryAmerican Journal of Physiology-Renal Physiology, 2010
- Analyzing real-time PCR data by the comparative CT methodNature Protocols, 2008
- An approach to elucidate potential mechanism of renal toxicity of arsenic trioxideExperimental Hematology, 2007
- Dysregulation of renal MMP-3 and MMP-7 in canine X-linked Alport syndromePediatric Nephrology, 2005
- In Vivo Chromatin Remodeling Events Leading to Inflammatory Gene Transcription under Diabetic ConditionsJournal of Biological Chemistry, 2004